| Filed On | Filing |
|---|---|
| 08 Sep 2026 |
8-K/A: Entry into a Material Definitive Agreement
On August 28, 2026, Indaptus Therapeutics, Inc. (the “Company”) entered into an Amended and Restated At the Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), which amends and restates in it... |
| 24 Apr 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On April 17, 2026, the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”) appointed Mr. Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors of the Board, effective April 22, 2026. |
| 16 Aug 2021 | 8-K/A: Costs Associated with Exit or Disposal Activities; Material Impairments +1 more |
Loading...
